Interleukins can have a wide variety of pro- or anti- tumor effects and many have been therapeutically targeted in CRC clinical trials including IL-2, IL-12, IL-11, IL-6, IL-α, and IL-1β. This evidence concerns the gene IL1B and neoplasm.